Feasibility and Functionality of fPAM Imaging in Melanoma (fPAM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00776945 |
Recruitment Status :
Terminated
(no funding)
First Posted : October 22, 2008
Last Update Posted : June 8, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Melanoma |
Study Type : | Observational |
Actual Enrollment : | 2 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Characterization and Early Diagnosis of Melanoma |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | December 2014 |

- fPAM is a hybrid imaging technique that detects absorbed diffuse photons ultrasonically through the photoacoustic (PA) effect [ Time Frame: baseline ]Evaluate pigmented lesions for depth, width, total hemoglobin saturation, melanin distribution, and melanin concentration using fPAM in vivo and ex vivo
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adult patients (> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent.
Exclusion Criteria:
- Patients with melanomas < 1mm.
- Pregnant females.
- Children and young adults < 18 yrs of age and patients who are unable to give informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776945
United States, Missouri | |
Washington University School of Medicine | |
Saint Louis, Missouri, United States, 63110 | |
Washington University | |
Saint Louis, Missouri, United States, 63110 | |
Washington University School of Medicine | |
St. Louis, Missouri, United States, 63110 |
Principal Investigator: | Lynn A Cornelius, MD | Washington University School of Medicine |
Responsible Party: | Lynn Cornelius, MD, Chief, Division of Dermatology, Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00776945 |
Other Study ID Numbers: |
07-0635 |
First Posted: | October 22, 2008 Key Record Dates |
Last Update Posted: | June 8, 2015 |
Last Verified: | November 2013 |
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas |